Global Bronchodilators Market to Reach $45 Billion by 2030
The global market for Bronchodilators estimated at US$31.2 Billion in the year 2022, is projected to reach a revised size of US$45 Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2022-2030. Asthma, one of the segments analyzed in the report, is projected to record a 5.3% CAGR and reach US$19.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Chronic Obstructive Pulmonary Disease segment is readjusted to a revised 4.5% CAGR for the next 8-year period.The U.S. Market is Estimated at $8.5 Billion, While China is Forecast to Grow at 7.9% CAGR
The Bronchodilators market in the U.S. is estimated at US$8.5 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$9.7 Billion by the year 2030 trailing a CAGR of 7.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.4% and 3.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.1 Billion by the year 2030.Select Competitors (Total 42 Featured) -
- Ache Laboratorios Farmaceuticos
- Aquinox Pharmaceuticals
- AstraZeneca
- BioMarck Pharmaceuticals
- Boehringer Ingelheim
- F. Hoffmann-La Roche
- Gilead Sciences
- GlaxoSmithKline plc
- Innoviva
- MediciNova
- Merck & Co., Inc.
- Novartis Ag
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- Bronchodilators - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Bronchodilators Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Bronchodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
TABLE 3: World Historic Review for Bronchodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 4: World 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
TABLE 6: World Historic Review for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 7: World 16-Year Perspective for Asthma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
TABLE 9: World Historic Review for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 10: World 16-Year Perspective for Chronic Obstructive Pulmonary Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
TABLE 12: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 13: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
TABLE 15: World Historic Review for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 16: World 16-Year Perspective for Anticholinergics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
TABLE 18: World Historic Review for Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 19: World 16-Year Perspective for Combination Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Phosphodiesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
TABLE 21: World Historic Review for Phosphodiesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 22: World 16-Year Perspective for Phosphodiesterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Sympathomimetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
TABLE 24: World Historic Review for Sympathomimetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 25: World 16-Year Perspective for Sympathomimetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
TABLE 2: World Recent Past, Current & Future Analysis for Bronchodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
TABLE 3: World Historic Review for Bronchodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 4: World 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
TABLE 6: World Historic Review for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 7: World 16-Year Perspective for Asthma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
TABLE 9: World Historic Review for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 10: World 16-Year Perspective for Chronic Obstructive Pulmonary Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
TABLE 12: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 13: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
TABLE 15: World Historic Review for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 16: World 16-Year Perspective for Anticholinergics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
TABLE 18: World Historic Review for Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 19: World 16-Year Perspective for Combination Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Phosphodiesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
TABLE 21: World Historic Review for Phosphodiesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 22: World 16-Year Perspective for Phosphodiesterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Sympathomimetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
TABLE 24: World Historic Review for Sympathomimetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 25: World 16-Year Perspective for Sympathomimetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
UNITED STATES
TABLE 27: USA Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 28: USA 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 29: USA Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 30: USA Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 31: USA 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 34: Canada 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 35: Canada Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 37: Canada 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
JAPAN
TABLE 39: Japan Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 40: Japan 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 41: Japan Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 43: Japan 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
CHINA
TABLE 45: China Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 46: China 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 47: China Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 48: China Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 49: China 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
EUROPE
TABLE 51: Europe Historic Review for Bronchodilators by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 52: Europe 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 55: Europe 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 58: Europe 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
FRANCE
TABLE 60: France Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 61: France 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 62: France Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 63: France Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 64: France 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
GERMANY
TABLE 66: Germany Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 67: Germany 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 68: Germany Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 70: Germany 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
ITALY
TABLE 71: Italy Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 73: Italy 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 74: Italy Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 76: Italy 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
UNITED KINGDOM
TABLE 78: UK Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 79: UK 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 80: UK Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 81: UK Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 82: UK 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
SPAIN
TABLE 83: Spain Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 84: Spain Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 85: Spain 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 86: Spain Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 88: Spain 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
RUSSIA
TABLE 89: Russia Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 90: Russia Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 91: Russia 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 92: Russia Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 94: Russia 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
REST OF EUROPE
TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 96: Rest of Europe Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 97: Rest of Europe 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 100: Rest of Europe 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
ASIA-PACIFIC
TABLE 102: Asia-Pacific Historic Review for Bronchodilators by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 103: Asia-Pacific 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
AUSTRALIA
REST OF ASIA-PACIFIC
LATIN AMERICA
BRAZIL
MEXICO
REST OF LATIN AMERICA
MIDDLE EAST
ISRAEL
SAUDI ARABIA
UNITED ARAB EMIRATES
REST OF MIDDLE EAST
AFRICA
- Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
TABLE 27: USA Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 28: USA 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 29: USA Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 30: USA Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 31: USA 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 34: Canada 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 35: Canada Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 37: Canada 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
JAPAN
- Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
TABLE 39: Japan Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 40: Japan 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 41: Japan Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 43: Japan 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
CHINA
- Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
TABLE 45: China Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 46: China 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 47: China Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 48: China Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 49: China 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
EUROPE
- Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
TABLE 51: Europe Historic Review for Bronchodilators by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 52: Europe 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 55: Europe 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 58: Europe 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
FRANCE
- Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
TABLE 60: France Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 61: France 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 62: France Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 63: France Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 64: France 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
GERMANY
- Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
TABLE 66: Germany Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 67: Germany 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 68: Germany Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 70: Germany 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
ITALY
TABLE 71: Italy Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 73: Italy 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 74: Italy Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 76: Italy 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
UNITED KINGDOM
- Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
TABLE 78: UK Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 79: UK 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 80: UK Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 81: UK Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 82: UK 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
SPAIN
TABLE 83: Spain Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 84: Spain Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 85: Spain 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 86: Spain Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 88: Spain 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
RUSSIA
TABLE 89: Russia Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 90: Russia Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 91: Russia 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 92: Russia Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 94: Russia 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
REST OF EUROPE
TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 96: Rest of Europe Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 97: Rest of Europe 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 100: Rest of Europe 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
ASIA-PACIFIC
- Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
TABLE 102: Asia-Pacific Historic Review for Bronchodilators by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 103: Asia-Pacific 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2023 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2023 & 2030
AUSTRALIA
- Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
- Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
REST OF ASIA-PACIFIC
LATIN AMERICA
- Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
BRAZIL
MEXICO
REST OF LATIN AMERICA
MIDDLE EAST
- Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
ISRAEL
SAUDI ARABIA
UNITED ARAB EMIRATES
REST OF MIDDLE EAST
AFRICA
- Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ache Laboratorios Farmaceuticos
- Aquinox Pharmaceuticals
- AstraZeneca
- BioMarck Pharmaceuticals
- Boehringer Ingelheim
- F. Hoffmann-La Roche
- Gilead Sciences
- GlaxoSmithKline plc
- Innoviva
- MediciNova
- Merck & Co., Inc.
- Novartis Ag
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 93 |
Published | March 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 32.88 Billion |
Forecasted Market Value ( USD | $ 45 Billion |
Regions Covered | Global |